BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23922377)

  • 1. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.
    Li YP; Liang ZL; Xia JL; Wu JY; Wang L; Song LF; Mao QY; Wen SQ; Huang RG; Hu YS; Yao X; Miao X; Wu X; Li RC; Wang JZ; Yin WD
    J Infect Dis; 2014 Jan; 209(1):46-55. PubMed ID: 23922377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.
    Li YP; Liang ZL; Gao Q; Huang LR; Mao QY; Wen SQ; Liu Y; Yin WD; Li RC; Wang JZ
    Vaccine; 2012 May; 30(22):3295-303. PubMed ID: 22426327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.
    Zhu F; Xu W; Xia J; Liang Z; Liu Y; Zhang X; Tan X; Wang L; Mao Q; Wu J; Hu Y; Ji T; Song L; Liang Q; Zhang B; Gao Q; Li J; Wang S; Hu Y; Gu S; Zhang J; Yao G; Gu J; Wang X; Zhou Y; Chen C; Zhang M; Cao M; Wang J; Wang H; Wang N
    N Engl J Med; 2014 Feb; 370(9):818-28. PubMed ID: 24571754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.
    Hu YM; Wang X; Wang JZ; Wang L; Zhang YJ; Chang L; Liang ZL; Xia JL; Dai QG; Hu YL; Mao QY; Zhu FC; Song YF; Gao F; Chen JT
    Clin Vaccine Immunol; 2013 Dec; 20(12):1805-11. PubMed ID: 24108780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Zhu FC; Liang ZL; Li XL; Ge HM; Meng FY; Mao QY; Zhang YT; Hu YM; Zhang ZY; Li JX; Gao F; Chen QH; Zhu QY; Chu K; Wu X; Yao X; Guo HJ; Chen XQ; Liu P; Dong YY; Li FX; Shen XL; Wang JZ
    Lancet; 2013 Mar; 381(9871):1037-45. PubMed ID: 23352749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
    Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
    Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inactivated enterovirus 71 vaccine in healthy children.
    Li R; Liu L; Mo Z; Wang X; Xia J; Liang Z; Zhang Y; Li Y; Mao Q; Wang J; Jiang L; Dong C; Che Y; Huang T; Jiang Z; Xie Z; Wang L; Liao Y; Liang Y; Nong Y; Liu J; Zhao H; Na R; Guo L; Pu J; Yang E; Sun L; Cui P; Shi H; Wang J; Li Q
    N Engl J Med; 2014 Feb; 370(9):829-37. PubMed ID: 24571755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.
    Wei M; Meng F; Wang S; Li J; Zhang Y; Mao Q; Hu Y; Liu P; Shi N; Tao H; Chu K; Wang Y; Liang Z; Li X; Zhu F
    J Infect Dis; 2017 Jan; 215(1):56-63. PubMed ID: 28077584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial.
    Shenyu W; Jingxin L; Zhenglun L; Xiuling L; Qunying M; Fanyue M; Hua W; Yuntao Z; Fan G; Qinghua C; Yuemei H; Xin Y; Huijie G; Fengcai Z
    J Infect Dis; 2014 Oct; 210(7):1073-82. PubMed ID: 24625805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.
    Tambyah PA; Oon J; Asli R; Kristanto W; Hwa SH; Vang F; Karwal L; Fuchs J; Santangelo JD; Gordon GS; Thomson C; Rao R; Dean H; Das SC; Stinchcomb DT
    Vaccine; 2019 Jul; 37(31):4344-4353. PubMed ID: 31230881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu FC; Meng FY; Li JX; Li XL; Mao QY; Tao H; Zhang YT; Yao X; Chu K; Chen QH; Hu YM; Wu X; Liu P; Zhu LY; Gao F; Jin H; Chen YJ; Dong YY; Liang YC; Shi NM; Ge HM; Liu L; Chen SG; Ai X; Zhang ZY; Ji YG; Luo FJ; Chen XQ; Zhang Y; Zhu LW; Liang ZL; Shen XL
    Lancet; 2013 Jun; 381(9882):2024-32. PubMed ID: 23726161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial.
    Zhang W; Kong Y; Jiang Z; Li C; Wang L; Xia J
    Hum Vaccin Immunother; 2016 Apr; 12(4):922-30. PubMed ID: 26837471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.
    Hu Y; Zeng G; Chu K; Zhang J; Han W; Zhang Y; Li J; Zhu F
    Hum Vaccin Immunother; 2018 Jun; 14(6):1517-1523. PubMed ID: 29482422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial.
    Xu Q; Cao Q; Yang W; Liu X; Liu H; Tian X; Li J; Fang X; Jia N; Zeng G; Xu A
    Vaccine; 2020 Mar; 38(12):2671-2677. PubMed ID: 32067817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial.
    Hung MC; Cho CY; Chen CJ; Lai CC; Wu KG
    Vaccine; 2019 Sep; 37(37):5559-5566. PubMed ID: 31399275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safety study of inactivated Enterovirus 71 vaccine.
    Zhou XB; Lu JJ; Jiang YS; Huo Y; Wang JF; Zhou KF; Li B
    Hum Vaccin Immunother; 2013 Jul; 9(7):1430-7. PubMed ID: 23571172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.
    Aichinger G; Ehrlich HJ; Aaskov JG; Fritsch S; Thomasser C; Draxler W; Wolzt M; Müller M; Pinl F; Van Damme P; Hens A; Levy J; Portsmouth D; Holzer G; Kistner O; Kreil TR; Barrett PN
    Vaccine; 2011 Nov; 29(50):9376-84. PubMed ID: 22001875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
    Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
    Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months.
    Jin P; Li J; Zhang X; Meng F; Zhou Y; Yao X; Gan Z; Zhu F
    Hum Vaccin Immunother; 2016 Apr; 12(4):916-21. PubMed ID: 26751765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months.
    Gu W; Zeng G; Hu YM; Hu YS; Zhang Y; Hu YL; Wang Y; Li JX; Zhu FC
    Expert Rev Vaccines; 2018 Mar; 17(3):257-262. PubMed ID: 29363365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.